Moderna Inc (MRNA)vsRevolution Medicines Inc (RVMD)
MRNA
Moderna Inc
$47.44
-8.04%
HEALTHCARE · Cap: $19.80B
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 299765% more annual revenue ($2.23B vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -143.5%. MRNA earns a higher WallStSmart Score of 34/100 (F).
MRNA
Avoid34
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.2%
Fair Value
$140.45
Current Price
$47.44
$93.01 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 260.2% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
ROE of -43.1% — below average capital efficiency
Earnings declined 85.1%
Negative free cash flow — burning cash
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 260.2% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Piotroski F-Score, Return on Equity, EPS Growth.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
MRNA profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
MRNA is growing revenue faster at 260.2% — sustainability is the question.
RVMD generates stronger free cash flow (-356M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (34/100 vs 24/100) and 260.2% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?